肾上腺素剂量、目标温度管理与院外心脏骤停成人神经及生存结局分析
该回顾性队列纳入2008年1月1日至2018年12月31日美国西雅图与金县14 612例非创伤性院外心脏骤停成人中5253例恢复自主循环且入院时昏迷者,中位肾上腺素剂量2.0 mg(IQR 1.0-3.0 mg),3052例(58.1%)接受TTM。肾上腺素每增加1 mg,神经良好生存(CPC 1-2)的OR为0.46(95%CI 0.42-0.50)、出院生存OR为0.47(95%CI 0.43-0.51)。校正Utstein协变量后,TTM与肾上腺素剂量存在交互,CPC 1-2交互OR 1.36(95%CI 1.22-1.51)、生存交互OR 1.37(95%CI 1.24-1.51),即可除颤与不可除颤心律分层后交互仍显著。作者认为TTM可能减弱高剂量肾上腺素的不良效应。
要点
- 肾上腺素每增加1 mg,神经良好生存(CPC 1-2)OR 0.46(95%CI 0.42-0.50),出院生存OR 0.47(95%CI 0.43-0.51)。
- TTM与肾上腺素剂量存在交互:校正Utstein协变量后CPC 1-2交互OR 1.36(95%CI 1.22-1.51),出院生存交互OR 1.37(95%CI 1.24-1.51)。
- 按初始心律分层交互仍显著:可除颤心律交互OR 1.20(95%CI 1.04-1.39),不可除颤心律交互OR 1.24(95%CI 1.07-1.45)。
- 研究人群为恢复自主循环且入院时昏迷的院外心脏骤停成人,中位肾上腺素剂量2.0 mg(IQR 1.0-3.0 mg),58.1%接受TTM。
- 作者认为TTM可能减弱高剂量肾上腺素的不良效应,该关联来自回顾性队列,需进一步研究。
适用人群与场景
- 2008年1月1日至2018年12月31日美国西雅图与金县14 612例非创伤性院外心脏骤停成人中,恢复自主循环且入院时昏迷的5253例(中位年龄63岁,IQR 51-74岁;3460例[65.8%]男性)。
研究设计与关键结果
- 回顾性队列研究,评估14 612例成人,最终纳入5253例;中位肾上腺素剂量2.0 mg(IQR 1.0-3.0 mg),3052例(58.1%)接受TTM。
- 1889例(36.0%)存活且CPC 1-2,2177例(41.4%)存活至出院。
- 肾上腺素剂量增加与CPC 1-2可能性降低相关(每增加1 mg,OR 0.46;95%CI 0.42-0.50),与出院生存降低相关(OR 0.47;95%CI 0.43-0.51)。
- 校正Utstein协变量后,TTM与肾上腺素剂量交互:CPC 1-2交互OR 1.36(95%CI 1.22-1.51),出院生存交互OR 1.37(95%CI 1.24-1.51)。
- 按初始心律分层,可除颤心律交互OR 1.20(95%CI 1.04-1.39),不可除颤心律交互OR 1.24(95%CI 1.07-1.45)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为TTM可能减弱高剂量肾上腺素的不良效应,该结论来自回顾性队列,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Epinephrine improves return of spontaneous circulation after out-of-hospital cardiac arrest (OHCA). These beneficial cardiac effects do not directly translate to better neurologic outcomes, possibly because of epinephrine-induced microvascular effects that produce critical brain ischemia.
OBJECTIVE: To examine whether targeted temperature management (TTM) modifies the adverse association between increasing prehospital epinephrine dose and neurologically favorable survival.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed 14 612 adults from Seattle and King County, Washington, with nontraumatic OHCA between January 1, 2008, and December 31, 2018, and included those who achieved return of spontaneous circulation and were unconscious at hospital admission. Data analysis was performed from April 2021 to May 2022.
EXPOSURES: Epinephrine dose and TTM during prehospital resuscitation.
MAIN OUTCOMES AND MEASURES: Favorable neurologic survival (Cerebral Performance Category [CPC] 1 or 2) and survival to hospital discharge.
RESULTS: Of the 14 612 assessed adults, 5253 (median age, 63 years; IQR, 51-74 years; 3460 [65.8%] male) were eligible for the study. The median epinephrine dose was 2.0 mg (IQR, 1.0-3.0 mg); 3052 patients (58.1%) received TTM. In all, 1889 patients (36.0%) survived with CPC 1 to 2, and 2177 (41.4%) survived to discharge. Increasing doses of epinephrine were associated with a decreasing likelihood of CPC 1 to 2 (odds ratio [OR], 0.46; 95% CI 0.42-0.50 for each additional milligram of epinephrine) and survival (OR, 0.47; 95% CI, 0.43-0.51). The dose-dependent epinephrine association was modified by TTM. After adjusting for Utstein covariates, TTM was associated with a relative stepwise improvement in odds of CPC 1 to 2 (interaction OR, 1.36; 95% CI, 1.22-1.51) and survival (interaction OR, 1.37; 95% CI, 1.24-1.51). A significant interaction was also observed when the analysis was stratified according to initial rhythm among shockable OHCA and nonshockable OHCA (shockable interaction OR, 1.20; 95% CI, 1.04-1.39; and nonshockable interaction OR, 1.24, 95% CI, 1.07-1.45).
CONCLUSIONS AND RELEVANCE: This cohort study found an interaction between TTM and epinephrine dose such that the beneficial association of TTM increased with increasing epinephrine dose, suggesting that TTM may attenuate the adverse effects of higher-dose epinephrine.
参考来源
- Yang BY, Bulger N, Chocron R, et al. Analysis of Epinephrine Dose, Targeted Temperature Management, and Neurologic and Survival Outcomes Among Adults With Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2022. PMID: 35951327. doi:10.1001/jamanetworkopen.2022.26191
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。